Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine

Xenobiotica

Volumn 38, Issue 10, 2008, Pages 1305-1312

  Mealey, K L ^a   Jabbes, M ^a   Spencer, E ^a   Akey, J M ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Canine; Cytochrome P450 (CYP) 3A; Intestine

Indexed keywords

CYTOCHROME; CYTOCHROME P450 3A12; CYTOCHROME P450 3A26; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SAFETY; DUODENUM; INTESTINE; LIVER; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DUODENUM; GENE EXPRESSION; LIVER; RNA, MESSENGER;

CANIS FAMILIARIS;

EID: 53849090689     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802446146     Document Type: Article

References (19)

1. Baldwin SJ, Bramhall JL, Ashby CA, Yue L, Murdock PR, Hood SR, Ayrton AD, Clarke SE. 2006. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metabolism and Disposition 34:1063-1069.
2. Fraser DJ, Feyereisen R, Harlow GR, Halpert JR. 1997. Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. Journal of Pharmacology and Experimental Therapeutics 283:1425-1432.
3. Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K, Court MH. 2000. Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: Reed and gender differences. Xenobiotica 30:575-588.
4. He P, Court MH, Greenblatt DJ, Von Moltke LL. 2005. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clinical Pharmacology and Therapeutics 77:373-387.
5. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. 2002. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metabolism and Disposition 30:1108-1114.
6. Kolars JC, Awni WM, Merion RM, Watkins PB. 1991. First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
7. Komura H, Iwaki M. 2008. Species differences in vitro and in vivo small intestinal metabolism of CYP3A substrates. Journal of Pharmaceutical Science 97:1775-1800.
8. Kukanich B, Lascelles BD, Aman AM, Mealey KL, Papich MG. 2005. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. Journal of Veterinary Pharmacology and Therapeutics 28:461-466.
9. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. 2007. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metabolism Reviews 39:699-721.
10. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. 1994. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metabolism and Disposition 22:947-955.
11. Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD, Shou M. 2005. Selective inhibition of dog hepatic CYP2B11 and CYP3A12. Journal of Pharmacology and Experimental Therapeutics 313:518-528.
12. Marathe PH, Rodrigues AD. 2006. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions. Current Opinion in Drug Metabolism 7:687-704.
13. Neff MW, Robertson KR, Wong AK, Safra N, Broman KW, Slatkin M, Mealey KL, Pedersen NC. 2004. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proceedings of the National Academy of Science USA 101:11725-11730.
14. Nishibe Y, Wakabayashi M, Harauchi T, Ohno K. 1998. Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica 28:549-557.
15. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. 2006. The human intestinal cytochrome P450 'pie'. Drug Metabolism and Disposition 34:880-886.
16. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. 1997. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics 283:1552-1562.
17. Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, Yan B, Schoenhard GL. 1999. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metabolism and Disposition 27:1133-1142.
18. Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, Rushmore TH. 2003. Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metabolism and Disposition 31:1161-1169.
19. Smith BJ, Zupan LA, Hu JK, Diters RW, Gibson GW, Norton JN. 1996. Characterization of the effects of tebufelone on hepatic cytochromes P450 in the beagle dog. Drug Metabolism and Disposition 24:523-528.